Biologic Therapy to Prevent Osteoarthritis After ACL Injury
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03968913|
Recruitment Status : Not yet recruiting
First Posted : May 30, 2019
Last Update Posted : May 30, 2019
|First Submitted Date ICMJE||May 24, 2019|
|First Posted Date ICMJE||May 30, 2019|
|Last Update Posted Date||May 30, 2019|
|Estimated Study Start Date ICMJE||September 1, 2019|
|Estimated Primary Completion Date||August 31, 2022 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||MRI [ Time Frame: MRI images will be obtained at 3, 6, 9, 12 and 24 months following surgery ]
Change in cartilage signal intensity on magnetic resonance imaging
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||No Changes Posted|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title ICMJE||Biologic Therapy to Prevent Osteoarthritis After ACL Injury|
|Official Title ICMJE||Biologic Therapy to Prevent Osteoarthritis After ACL Injury|
Anterior cruciate ligament (ACL) injuries are extremely common. On average, 50% of individuals suffering an ACL injury will develop radiographic osteoarthritis (OA) 10 to 20 years after injury. Unfortunately, ACL reconstruction does not prevent risk of future OA.
Interleukin-1 (IL-1) levels in the human knee joint increase transiently after an ACL injury. In animal experiments, if interleukin-1 levels are increased in the joint, this alone causes arthritis to occur. Interleukin-1 receptor antagonist (IL-1Ra) is a naturally occurring inhibitor of IL-1. However, in ACL injuries the balance of these two proteins is disturbed transiently after injury, with the effects of IL-1 dominating this balance. In a large animal model of ACL injury, injection of IL-1Ra into the knee joint after ACL injury significantly decreased the amount of arthritis that was later observed.
Thus, the investigators hypothesize that injection of IL-1 inhibitor (IL-1Ra) into the knee joint of patients suffering recent ACL injury will decrease the incidence of cartilage damage.
After appropriate IRB approval, a total of 48 active patients will be randomized into one of three treatment groups. Group 1 will receive removal of the knee joint fluid (aspiration of hemarthrosis) using a needle and syringe within 1 week of injury. Following aspiration of the knee joint, an injection of 5 milliliters (mls) of sterile saline (as a placebo control) will be administered. In addition, a second knee aspiration procedure and an injection of 5mls of sterile saline into the injured knee joint will be performed at 10 days post-injury. Group 2 will receive aspiration of the knee hemarthrosis as described in group 1 as well as intra-articular administration of 150mg (~5mls) of anakinra (rhIL-1Ra) within 7 days of ACL injury. In addition, a second knee aspiration and injection of 5mls of sterile saline into the injured knee joint will be performed at 10 days post-injury. Group 3 patients will receive aspiration of the knee hemarthrosis and injection of anakinra as described in group 2 as well as a second intra-articular knee injection of anakinra (150mg, ~5mls) on post-injury day 10. Thus, all patients in this randomized placebo-controlled trial will undergo two injection procedures prior to surgery.
Rather than waiting years to observe the sequelae, T1rho MRI technology will be used to compare MRI findings among patients in these 3 treatment groups as well as an uninjured control group. In addition, the investigators will analyze subjects self-reported function and pain scores as well as urinary levels of cartilage breakdown products over time. These MRI, urine and subjective outcome assessments will be obtained prior to surgery and then again at 3, 6, 9, 12 and 24 months post-operatively.
After appropriate IRB approval at total of 48 active patients who meet the inclusion criteria listed above will be randomized into three treatment groups: Group 1 (n = 16) will undergo ultrasound guided arthrocentesis of the knee hemarthrosis at the time of presentation in clinic. Following aspiration of the knee joint hemarthrosis, an injection of 5 milliliters (mls) of 0.9% sodium chloride solution (sterile saline) will be administered as a placebo control. In addition, a second aspiration of knee joint fluid and injection of sterile saline into the injured knee joint will be performed at 10 days post-injury. Group 2 (n = 16) will undergo arthrocentesis as described in group 1 as well as intra-articular administration of 150mg (~5mls) of anakinra (rhIL-1Ra) within 7 days of ACL injury. In addition, repeat knee joint fluid aspiration and a second injection of 5mls of sterile saline into the injured knee joint will be performed at 10 days post-injury. Group 3 patients will receive arthrocentesis and injection of anakinra as described in group 2 as well as a second knee joint aspiration and intra-articular knee injection of anakinra (150mg, ~5mls) on post-injury day 10. Thus, all patients will undergo two ultrasound guided knee aspiration and injection procedures prior to surgery. The first injection will be after the arthrocentesis procedure to remove the hemarthrosis associated with acute ACL injury. To minimize pain and discomfort the same needle stick will be used to aspirate the hemarthrosis and to inject the saline or anakinra depending on the patient's treatment group. The second knee arthrocentesis and injection in each patient will also be performed under ultrasound-guidance at 10 days after injury. Some patient's injuries may fall on a day where performing these aspiration and injection procedures exactly 10 days after injury is not possible due to constraints of the work week (i.e. Monday through Friday). In this case the procedures will be performed on the next consecutive work day closest to the 10 days post-injury time point. An additional arthrocentesis procedure will be performed at the time of surgery.
Patients in all 3 groups will be followed longitudinally with repeat MR imaging that includes T1rho sequences being obtained at 3, 6, 12 and 24 months post-operatively (Aim 1). The MRI studies performed in this investigation will be non-arthrogram studies without intra-articular or intravenous contrast.
Study patients in all 3 groups will undergo pre-operative collection of urine and knee joint fluid as described above. These time points include: i) at the time of enrollment into the study (within 7 days of injury), ii) at 10 days after injury, iii) on the day of surgery (within 30 days of injury). In addition, urine and knee joint fluid collection will be performed at the initial post-operative visit (approximately 10 days after surgery) followed by collection of urine alone at 3, 6, 12 and 24 months post-operatively in all treatment groups. Urine and arthrocentesis samples will be analyzed for the presence of inflammatory cytokines and cartilage breakdown biomarkers (Aim 2) according to Osteoarthritis Research Society International guidelines (see cytokine and biomarker assays section below for further details). Given, that multiple studies have demonstrated resolution of cytokine abnormalities by 2 to 4 weeks after ACL injury, urine assessments of cytokine assays (IL-1, etc.) will not be conducted beyond 3 months post-operatively. However, ELISAs for cartilage biomarkers will be performed on urine collected at each time point throughout the duration of the study. Validated patient reported outcome assessments (KOOS, VAS and PROMIS) will be completed at initial presentation as well as at 3, 6, 12 and 24 month post-operatively (Aim 3).
This study will be a single-blinded design and all aspects of the study design will be disclosed to subjects during the informed consent process. Given that anakinra needs to be ordered by the physician from the pharmacy on the day of injection, the physician performing the injection will not be blinded to which patients receive anakinra treatments. However, the patients will be blinded regarding which treatment they receive. All patients will receive injections of the same volume and using the same type of needle and syringe. In addition, the radiologist interpreting the MRI studies will be blinded to which treatment the patients receive. The physician administering the injections into the joint will not be involved in interpreting the MRI findings and will not be present when subjects complete the patient-reported outcome measures. In addition, the synovial fluid and urine biomarker data will be analyzed in a coded fashion in conjunction with a statistician to avoid bias in the statistical analysis.
|Study Type ICMJE||Interventional|
|Study Phase ICMJE||Early Phase 1|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Randomized, placebo controlled study with 3 treatment groups: 1) placebo only, 2) one dose of study medication, 3) two doses of study medicationMasking: Double (Participant, Outcomes Assessor)
single blindedPrimary Purpose: Treatment
|Condition ICMJE||Anterior Cruciate Ligament Injuries|
|Study Arms ICMJE||
|Publications *||Kraus VB, Birmingham J, Stabler TV, Feng S, Taylor DC, Moorman CT 3rd, Garrett WE, Toth AP. Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254). Osteoarthritis Cartilage. 2012 Apr;20(4):271-8. doi: 10.1016/j.joca.2011.12.009. Epub 2012 Jan 10.|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Not yet recruiting|
|Estimated Enrollment ICMJE
|Original Estimated Enrollment ICMJE||Same as current|
|Estimated Study Completion Date ICMJE||August 31, 2022|
|Estimated Primary Completion Date||August 31, 2022 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages ICMJE||18 Years to 35 Years (Adult)|
|Accepts Healthy Volunteers ICMJE||Yes|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT03968913|
|Other Study ID Numbers ICMJE||19-000724|
|Has Data Monitoring Committee||Yes|
|U.S. FDA-regulated Product||
|IPD Sharing Statement ICMJE||
|Responsible Party||Thomas Kremen, MD, University of California, Los Angeles|
|Study Sponsor ICMJE||University of California, Los Angeles|
|Collaborators ICMJE||Orthopedic Research and Education Foundation|
|Investigators ICMJE||Not Provided|
|PRS Account||University of California, Los Angeles|
|Verification Date||May 2019|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP